Denise Myshko

Demand for behavioral healthcare has surged, increasing costs for health plans and employers as millions of Americans struggle with mental illness, substance use disorders, and access challenges.

Researchers analyzing seven oncology therapies found most U.S. commercial plans treat subcutaneous and IV formulations equally, but five payers enforced IV-preferred policies, according to a poster released at the 2026 ASCO meeting.

The FDA has set a target action date of July 29, 2026, for Lytenava to treat patients with wet age-related macular degeneration. Outlook Therapeutics had successfully appealed a complete response letter issued in December 2025.

Prior authorization and high out-of-pocket costs impact blood cancer patients' access to oral cancer drugs, according to a poster at the 2026 ASCO Meeting.

The merger is expected to close in the third quarter. Both PBMs will operate as wholly owned subsidiaries of Healthcare Revolution Partners.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, argues that function-based tools offer a more equitable and clinically meaningful approach to pain management.

David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company's merger and how the combined company is positioned for the PBM market of the future.

If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient's pain.

Hofstra University and Northwell Health's jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.